Assessing the carbon footprint of French academic clinical trials using the NIHR method
Cécile Auriault1, Martine Tching-Sin2, Laetitia Biron3
1Pharmacy, CHU Nantes, Nantes, Pays de la Loire, France cecile.auriault@hotmail.fr.
Objectives:
This project aimed to assess the applicability of the National Institute for Health and Care Research (NIHR) tool to French academic studies and identify the carbon hotspots, with a view to discussing ways of mitigating their environmental impact.
Design:
Retrospective analysis.
Setting:
A completed single-centre phase I haematology trial TOCILAM (NCT04547062) and a completed multicentre phase III in intensive care REMICRUSH (NCT03960801).
Participants:
TOCILAM had a total number of 12 participants and REMICRUSH had a total number of 1150 participants.
Main Outcome Measures:
Total carbon emissions from each trial and the hotspots of those emissions.
Results:
The carbon footprint of the TOCILAM and REMICRUSH studies was estimated at 3.2 and 5.8 tonnes of CO2 equivalent, respectively. For these two studies, the hotspots were the Meetings and travel item followed by the clinical trial unit emissions.
Discussion:
The NIHR tool is easily applicable to the context of French academic clinical studies. The total estimated carbon footprint of the two clinical trials was generally lower than what has been reported in the literature for academic studies. However, areas for improvement have been identified.
More Related Videos
07:52Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department
Published on: January 29, 2011
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioavailability Study Design: Healthy Subjects Versus Patients
